Literature DB >> 20424990

Testosterone deficiency and exercise intolerance in heart failure: treatment implications.

Ferdinando Iellamo1, Giuseppe Rosano, Maurizio Volterrani.   

Abstract

Chronic heart failure (CHF) is characterized by a metabolic shift favoring catabolism with impairment in skeletal muscle bulk and function. There is evidence that low plasma levels of testosterone play a role in this shift, and that hypotestosteronemia could be involved in the impairment of skeletal muscle function and exercise tolerance, which characterize CHF syndrome. Testosterone supplementation at replacement doses has been hypothesized as a potential therapy to counteract anabolic deficiency in CHF also acting on pathophysiological mechanisms, which sustain the progression of CHF. Recent studies have indeed indicated that testosterone supplementation increases functional capacity and muscle performance in patients with CHF. This review summarizes current knowledge on the role of testosterone deficiency in exercise intolerance in CHF and the potential implications of testosterone therapy. The links between testosterone and exercise tolerance in CHF, as well as the potential mechanisms of testosterone benefits in CHF syndrome, are also emphasized. Finally, unsolved issues regarding testosterone therapy in CHF and directions for future research are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424990     DOI: 10.1007/s11897-010-0008-6

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  46 in total

1.  Acute haemodynamic effects of testosterone in men with chronic heart failure.

Authors:  Peter J Pugh; T Hugh Jones; Kevin S Channer
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

2.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting.

Authors:  S D Anker; A L Clark; M Kemp; C Salsbury; M M Teixeira; P G Hellewell; A J Coats
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

3.  Development of a ventilatory classification system in patients with heart failure.

Authors:  Ross Arena; Jonathan Myers; Joshua Abella; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Marco Guazzi
Journal:  Circulation       Date:  2007-04-23       Impact factor: 29.690

4.  Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure.

Authors:  Massimo F Piepoli; Agnieszka Kaczmarek; Darrel P Francis; L Ceri Davies; Mathias Rauchhaus; Ewa A Jankowska; Stefan D Anker; Alessandro Capucci; Waldemar Banasiak; Piotr Ponikowski
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

5.  Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension.

Authors:  Thomas W Storer; Lynne Magliano; Linda Woodhouse; Martin L Lee; Connie Dzekov; Jeanne Dzekov; Richard Casaburi; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

6.  Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.

Authors:  Ewa A Jankowska; Bartosz Biel; Jacek Majda; Alicja Szklarska; Monika Lopuszanska; Marek Medras; Stefan D Anker; Waldemar Banasiak; Philip A Poole-Wilson; Piotr Ponikowski
Journal:  Circulation       Date:  2006-10-09       Impact factor: 29.690

7.  Cardiomyoplasty - improvement of muscle fibre type transformation by an anabolic steroid (metenolone).

Authors:  M Czesla; G Mehlhorn; D Fritzsche; G Asmussen
Journal:  J Mol Cell Cardiol       Date:  1997-11       Impact factor: 5.000

8.  Testosterone administration to older men improves muscle function: molecular and physiological mechanisms.

Authors:  Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

9.  Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.

Authors:  Andrea D Coviello; Beth Kaplan; Kishore M Lakshman; Tai Chen; Atam B Singh; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

10.  Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.

Authors:  K K Miller; B M K Biller; C Beauregard; J G Lipman; J Jones; D Schoenfeld; J C Sherman; B Swearingen; J Loeffler; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

View more
  5 in total

1.  Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study.

Authors:  D Francomano; R Bruzziches; G Barbaro; A Lenzi; A Aversa
Journal:  J Endocrinol Invest       Date:  2014-03-18       Impact factor: 4.256

Review 2.  Testosterone in men with hypogonadism and high cardiovascular risk, Pros.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Massimo Fini
Journal:  Endocrine       Date:  2015-03-07       Impact factor: 3.633

3.  Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study.

Authors:  Jared W Magnani; Carlee B Moser; Joanne M Murabito; Lisa M Sullivan; Na Wang; Patrick T Ellinor; Ramachandran S Vasan; Emelia J Benjamin; Andrea D Coviello
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-03-08

4.  Testosterone level and mortality in elderly men with systolic chronic heart failure.

Authors:  Hai-Yun Wu; Xiao-Fei Wang; Jun-Hua Wang; Jiang-Yuan Li
Journal:  Asian J Androl       Date:  2011-06-20       Impact factor: 3.285

Review 5.  Exercise training as therapy for heart failure: current status and future directions.

Authors:  Jerome L Fleg; Lawton S Cooper; Barry A Borlaug; Mark J Haykowsky; William E Kraus; Benjamin D Levine; Marc A Pfeffer; Ileana L Piña; David C Poole; Gordon R Reeves; David J Whellan; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2015-01       Impact factor: 8.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.